Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Abstract High lipoprotein (a)[Lp (a)] concentrations are one of the most important genetically
determined risk factors for cardiovascular disease. Lp (a) concentrations are an enigmatic …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

Abstract Lipoprotein (a)[Lp (a)] became besides LDL cholesterol one of the most attractive
targets for intervention in cardiovascular disease. Strong genetic evidence supports the …

The initial studies focusing on lipoprotein (a)[Lp (a)] and its role in atherosclerotic
cardiovascular disease were conducted exclusively in Whites. Subsequently, multiple large …

Abstract In 2022, the European Atherosclerosis Society (EAS) published a new consensus
statement on lipoprotein (a)[Lp (a)], summarizing current knowledge about its causal …

This study reviews ancestral differences in the genetics of the LPA gene, risk categories of
elevated lipoprotein (a)[Lp (a)] as defined by guidelines, ancestry-specific Lp (a) risk …

Abstract Lipoprotein (a)[Lp (a)] is a source of residual risk in patients with atherosclerotic
cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies …

Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …